The DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.
Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Open accessAbstract
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder. Most existing treatments only provide symptomatic solutions. Here, we introduce currently available commercial drugs and new therapeutics, including repositioned drugs, to treat AD. Despite tremendous efforts, treatments targeting the hallmarks of AD show limited efficacy. Challenges in treating AD are partly caused by difficulties in penetrating the blood–brain barrier (BBB). Recently, nanoparticle (NP)-based systems have shown promising potential as precision medicines that can effectively penetrate the BBB and enhance the targeting ability of numerous drugs. Here, we describe how NPs enter the brain by crossing, avoiding, or disrupting the BBB. In addition, we provide an overview of the action of NPs in the microenvironment of the brain for the treatment of AD. Diverse systems, including liposomes, micelles, polymeric NPs, solid-lipid NPs, and inorganic NPs, have been investigated for NP drug loading to relieve AD symptoms, target AD hallmarks, and target moieties to diagnose AD. We also highlight NP-based immunotherapy, which has recently gained special attention as a potential treatment option to disrupt AD progression. Overall, this review focuses on recently investigated NP systems that represent innovative strategies to understand AD pathogenesis and suggests treatment and diagnostic modalities to cure AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of nanoparticles (NP), with sizes between 10 and 1000 nm, capable of encapsulating therapeutic molecules by targeting transport processes in the CNS, can improve the crossing of molecules through the BBB in neurological disorders and reach targeted brain regions [29,30,31].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Circumvention of the BBB via local routes can involve invasive procedures, such as intracerebroventricular and intrathecal ones, that deliver drugs directly into the CSF or brain tissue but remain inefficient and clinically restricted [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, prolonged BBB disruption associated with long-term treatment raises safety concerns, as it may facilitate neurotoxic effects in the brain [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because liposomes are made with lipids, they are biocompatible, biodegradable, and can fuse to cell membranes. Additionally, due to their size, fluidity, permeability, and composition, they are suitable for controlled drug release, while being versatile in the drug encapsulation, as they can encapsulate both lipophilic and hydrophilic drugs (dual solubility) [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, some molecules can cross the BBB by two main pathways, transcellular or paracellular, through the cell or the intercellular space, respectively [14].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This drug is designed to act on the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain [6].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“The abnormal processing of amyloid precursor protein (APP) by β- and γ-secretases produces extracellular non-vascular accumulation of Aβ40 and Aβ42 peptides [22,23].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“These latter preventive activities are supported by ApoE, which relies on TREM2 and activates microglia into the disease-associated microglia (DAM) state [174,175].”
BackgroundThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Research works printed but not linked: 1
- Chung, E.J., Leon, L., and Rinaldi, C. (2020). Chapter 21—Nanoemulsions. Nanoparticles for Biomedical Applications, Elsevier.
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 97
Pei, J., Kumarasamy, R. V., Jayaraman, S., Kanniappan, G. V., Long, Q., & Palanisamy, C. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102665 · Cited by 97
Khalid-Salako, F. A., Khaligh, S. S., Fathi, F., Demirci, O. C., Öncer, N., Kurt, H., & Yüce, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07366 · Cited by 83
Quantum dots: The cutting-edge nanotheranostics in brain cancer management
Chakraborty, P., Das, S. S., Dey, A., Chakraborty, A., Bhattacharyya, C., Kandimalla, R. J. L., Mukherjee, B., Gopalakrishnan, A. V., Singh, S. K., Kant, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.047 · Cited by 69
Metadata
- Authors
- Poudel, P., & Park, S.
- Affiliations
- Keimyung University (KR)
- Corresponding author
- Park, Soyeun
- ORCID
- Park, Soyeun
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-04-11
- Volume
- 14
- Issue
- 4
- Pages
- 835
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9026997
- OpenAlex
- W4223478480
- Cited by
- 124
- References
- 195
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 33 · 2023: 17 · 2022: 9
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Keimyung University (2019)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- Alzheimer's disease, nanoparticle drug delivery, blood-brain barrier, liposomes, micelles, polymeric nanoparticles, solid lipid nanoparticles, inorganic nanoparticles, Alzheimer's disease therapeutics, Alzheimer's disease diagnosis, neurodegeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. https://app.cochat.ai/papers/10.3390/pharmaceutics14040835
- The paper
- Poudel, P., & Park, S. (2022). Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14040835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.